{
    "2020-04-03": [
        [
            {
                "time": "",
                "original_text": "沃森生物 研发资本化率超高",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "研发资本化率",
                        "超高"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "智飞生物：股东吴冠江及一致行动人拟合计减持不超过1.85%股份 拟减持股份",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "股东",
                        "吴冠江",
                        "一致行动人",
                        "减持",
                        "1.85%"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "智飞生物：持股5%以上股东计划减持不超过总股本的1.85% 减持股份",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "持股5%以上",
                        "股东",
                        "计划减持",
                        "1.85%"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "智飞生物(300122.SZ)：吴冠江及一致行动人拟合计减持不超2960万股 拟减持股份",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "300122.SZ",
                        "吴冠江",
                        "一致行动人",
                        "减持",
                        "2960万股"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}